Table 1 Baseline clinical and biochemical characterization of the study population

Age

(years)

67 ± 6

68 ± 7

ns

Male

(%)

75

71

ns

BMI

(Kg/m²)

30 ± 6

29 ± 4

ns

Alcohol intake low/medium/high

(%)

50/38/12

54/38/8

ns

T2D duration

(years)

7 [4; 10.5]

7.5 [4; 12]

ns

Oral antidiabetic drugs

(%)

96

100

ns

Insulin

(%)

17

25

ns

Systolic blood pressure

(mmHg)

140 [131; 153]

145 [136; 159]

ns

Diastolic blood pressure

(mmHg)

83 [73; 90]

82 [73; 90]

ns

Fasting glucose

(mmol/L)

7.6 [6.0; 9.1]

7.8 [6.1; 10.7]

ns

HbA1_c

(mmol/mol)

52 [45; 56]

51 [44; 61]

ns

eGFR

(ml/min/1·73m²)

85 [77; 92]

87 [73; 98]

ns

CV events

(%)

17

17

ns

Total cholesterol

(mmol/L)

4.3 [3.9; 5.2]

4.3 [3.7; 5.1]

ns

HDL cholesterol

(mmol/L)

1.1 [1.0; 1.4]

1.1 [1.0; 1.3]

ns

LDL cholesterol

(mmol/L)

2.4 [1.8; 2.6]

2.5 [1.7; 3.3]

ns

Triglycerides

(mmol/L)

1.7 [1.3; 2.3]

1.5 [1.1; 1.8]

ns

ΣDEHP

(μg/g creatinine)

21.0 [13.3; 31.0]

22.6 [14.9; 40.0]

ns

MEHP

(μg/g creatinine)

3.6 [2.2; 4.9]

3.5 [2.2; 5.2]

ns

MEOHP

(μg/g creatinine)

4.8 [2.7; 6.8]

5.0 [3.5; 8.5]

ns

MEHHP

(μg/g creatinine)

13.6 [6.8; 18.5]

13.8 [8.2; 24.6]

ns

RMR1

4.8 [2.5; 5.5]

4.4 [2.5; 7.0]

ns

RMR2

0.4 [0.3; 0.4]

0.4 [0.3; 0.5]

ns